



# The Journal of Rheumatology

VOLUME 46: NO. 10

jrheum.org

OCTOBER 2019

## Editorials

- The Role of Natural Killer Cells in Inflammation in Active Adult-onset Still Disease**  
*J.Y. Jung, H.A. Kim* ..... 1253
- Treat-to-target Endpoint Definitions in Systemic Lupus Erythematosus: More Is Less?**  
*E.F. Morand, V. Golder* ..... 1256

## Rheumatoid Arthritis

- Effects of Sarilumab on RA as Reported by Patients Using the RA Impact of Disease Scale**  
*L. Gossec, V. Strand, C. Proudfoot, et al* ..... 1259
- Characteristics of Circulating Natural Killer Cells and Their Interferon- $\gamma$  Production in Active Adult-onset Still Disease**  
*Y. Shimojima, D. Kishida, K.I. Ueno, S. Ushiyama, T. Ichikawa, Y. Sekijima* ..... 1268

## Spondyloarthropathy

- Safety and Efficacy of Intravenous Golimumab in Adults with Ankylosing Spondylitis: Results through 1 Year of the GO-ALIVE Study**  
*J.D. Reveille, A. Deodhar, P.H. Caldron, et al* ..... 1277
- The Effect of Axial SpA on Mental Health: Results from the Atlas** *M. Garrido-Cumbrera, C.J. Delgado-Domínguez, D. Gálvez-Ruiz, C. Blanch Mur, V. Navarro-Compán, for the Atlas Working Group* ..... 1284

## Psoriatic Arthritis

- Association of Physical Activity and Medication with Enthesitis on Ultrasound in PsA**  
*K. Wervers, I. Herrings, J.J. Luime, et al* ..... 1290
- Peritenon Extensor Tendon Inflammation in PsA Is an Enthesitis-related Lesion** *C. Macía-Villa, S. Falcao, M. Gutierrez, J. Medina, H. Berner Hammer, E. De Miguel* ..... 1295

## Systemic Lupus Erythematosus

- Predictors of Remission and Low Disease Activity State in SLE: Data from a Multiethnic, Multinational Latin American Cohort**  
*M.F. Ugarte-Gil, D. Wojdyla, G.J. Pons-Estel, et al* ..... 1299
- Understanding Nonadherence with HCQ Therapy in SLE**  
*L.H. Liu, H.B. Fevrier, R. Goldfien, A. Hemmerling, L.J. Herrinton* ..... 1309

## Systemic Sclerosis

- Cyclophosphamide for SSc-related Interstitial Lung Disease: A Comparison of Scleroderma Lung Study I and II**  
*E.R. Volkman, D.P. Tashkin, M. Sim, et al* ..... 1316
- Factors Influencing Raynaud Condition Score Diary Outcomes in SSc**  
*J.D. Pauling, E. Reilly, T. Smith, T.M. Frech* ..... 1326

## Pediatric Rheumatology

- Longitudinal Health Status from Early Disease to Adulthood and Associated Prognostic Factors in JIA**  
*A. Tollisen, A.M. Selvaag, A. Aasland, A. Lerdal, B. Flato* ..... 1335

## Gout

- Use of Anakinra in Hospitalized Patients with Crystal-associated Arthritis**  
*J.W. Liew, G.C. Gardner* ..... 1345

## Images in Rheumatology

- Koebner Phenomenon in DM after Subcutaneous Methotrexate Injections**  
*P. Couture, C. Bachmeyer, J.B. Monfort* ..... 1350

Free online via JRheum Full Release option

Contents continued on page xii

---

# OMERACT 2018: International Consensus Conference on Outcome Measures in Rheumatology, Terrigal, Australia, May 2018

## Special Interest Groups, Part 2

### OMERACT 2018 Modified Patient-reported Outcome Domain Core Set in the Life Impact Area for Adult Idiopathic Inflammatory Myopathies

*M. Regardt, C.A. Mecoli, J.K. Park, et al. . . . .* 1351

### Pain Measurement in RMD: Where To Go from Here? Report from a Special Interest Group at OMERACT 2018

*A. Chiarotto, U. Kaiser, E. Choy, et al. . . . .* 1355

### Toward a Core Outcome Measurement Set for PMR: Report from the OMERACT 2018 Special Interest Group

*C.E. Owen, M. Yates, H. Twohig, et al. . . . .* 1360

### The 2018 OMERACT Synovial Tissue Biopsy Special Interest Group Report on Standardization of Synovial Biopsy Analysis

*M.D. Wechalekar, A. Najm, D.J. Veale, V. Strand. . . . .* 1365

### The SPECTRA Collaboration OMERACT Working Group: Criterion Validity of Joint Space Outcomes with High-resolution Peripheral Quantitative CT

*S.L. Manske, S.C. Brunet, S. Finzel, et al. . . . .* 1369

### Advancing Stiffness Measurement in Rheumatic Disease: Report from the Stiffness Special Interest Group at OMERACT 2018

*E.T. Craig, A.M. Orbai, S. Mackie, et al. . . . .* 1374

### Musculoskeletal Ultrasound in SLE: Systematic Literature Review by the Lupus Task Force of the OMERACT Ultrasound Working Group

*P.C. Wong, G. Lee, A. Delle Sedie, et al. . . . .* 1379

### OMERACT Definitions for US Pathologies and Elementary Lesions of Rheumatic Disorders 15 Years On

*G.A. Bruyn, A. Iagnocco, E. Naredo, et al, for the OMERACT Ultrasound Working Group. . . . .* 1388

### The OMERACT Stepwise Approach to Select and Develop Imaging Outcome Measurement Instruments: The Musculoskeletal US Example

*L. Terslev, E. Naredo, H.I. Keen, et al. . . . .* 1394

### Considerations for Evaluating and Recommending Worker Productivity Outcome Measures: An Update from the OMERACT Worker Productivity Group

*S.M. Verstappen, D. Lacaille, A. Boonen, et al. . . . .* 1401

### Adaptive Trial Designs in Rheumatology: Report from the OMERACT Special Interest Group

*T. Pickles, R. Alten, M. Boers, et al. . . . .* 1406

### OMERACT Development of a Core Domain Set of Outcomes for Shared Decision-making Interventions

*K. Toupin-April, J.L. Barton, L. Fraenkel, et al. . . . .* 1409

### Updating OMERACT Core Set of Domains for AAV: Patient Perspective Using the International Classification of Function, Disability, and Health

*N. Milman, E. McConville, J.C. Robson, et al. . . . .* 1415

## Correspondence

### Abnormal Cardiac Biomarkers in Patients with SLE and No Prior Heart Disease: The Role of Endomyocardial Biopsy

*G. De Luca, C. Campochiaro, L. Dagna . . . . .* 1421

### Reply K. Tselios, D.D. Gladman, P. Harvey,

*S. Akhtari, J. Su, M.B. Urowitz . . . . .* 1422

### Testing the Model for Predicting Effectiveness of Anakinra in Systemic JIA

*S. Ozen, S. Demir, E.D. Batu . . . . .* 1422

### Reply

*J. Tibaldi, B. Saccomanno, R. Caorsi, A. Ravelli. . . . .* 1424

Meetings . . . . .vi